2016 Quantum-Biosciences, LLC restructures and re-brands as AliquantumRx Inc.

Quantum-Biosciences LLC, a start-up company formed with the mission of development and commercialization of Cethromycin/QB101 for malaria prophylaxis, announces changes in its structure to a C-corp and its name to AliquantumRx Inc. David Sullivan, MD, professor of molecular microbiology and immunology at the Johns Hopkins Malaria Research Institute, the Johns Hopkins Bloomberg School of Public […]